| Basics |
Cue Biopharma, Inc.
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
|
| IPO Date: |
January 2, 2018 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$43.21M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.26 | 3.77%
|
| Avg Daily Range (30 D): |
$0.02 | 3.78%
|
| Avg Daily Range (90 D): |
$0.02 | 3.23%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.23M |
| Avg Daily Volume (30 D): |
.23M |
| Avg Daily Volume (90 D): |
.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
123 |
| Avg Trade Size (Sh.) (30 D): |
360 |
| Avg Trade Size (Sh.) (90 D): |
333 |
| Institutional Trades |
| Total Inst.Trades: |
183 |
| Avg Inst. Trade: |
$2.16M |
| Avg Inst. Trade (30 D): |
$.62M |
| Avg Inst. Trade (90 D): |
$.62M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$.62M |
| Avg Closing Trade (90 D): |
$.62M |
| Avg Closing Volume: |
243.1K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.41
|
$-.07
|
$-.09
|
|
Diluted EPS
|
$-.41
|
$-.07
|
$-.09
|
|
Revenue
|
$ 7.1M
|
$ 2.15M
|
$ 2.95M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -37.68M
|
$ -7.45M
|
$ -8.48M
|
|
Operating Income / Loss
|
$ -38.16M
|
$ -7.6M
|
$ -8.64M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -20.72M
|
$ -15.79M
|
$ 14.36M
|
|
PE Ratio
|
|
|
|
|
|
|
